Anzeige
Mehr »
Mittwoch, 08.10.2025 - Börsentäglich über 12.000 News
Defence-Aktie mit Ritterschlag: Regierungs-Einladung zur größten Militärmesse
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 940602 | ISIN: NL0000009538 | Ticker-Symbol: PHI1
Tradegate
08.10.25 | 11:25
24,120 Euro
+0,84 % +0,200
1-Jahres-Chart
KONINKLIJKE PHILIPS NV Chart 1 Jahr
5-Tage-Chart
KONINKLIJKE PHILIPS NV 5-Tage-Chart
RealtimeGeldBriefZeit
24,06024,08012:12
24,06024,08012:12
GlobeNewswire (Europe)
148 Leser
Artikel bewerten:
(0)

Royal Philips: Philips announces 5,000th Zenition mobile C-arm system installation, advancing access to high-quality, efficient surgical and interventional care worldwide

October 8, 2025

Global adoption milestone underscores innovation in mobile C-arm surgical and interventional imaging, with more than 15 million patients treated in 170+ countries every year

Amsterdam, the Netherlands - Royal Philips(NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the 5,000th installation of its Philips Zenition mobile surgery imaging system at Kolín Regional Hospital in the Czech Republic. Since its launch in 2019, Zenition has become a trusted solution in hospitals across more than 170 countries, enabling surgeons and interventional teams to perform image-guided procedures more efficiently, supporting improved treatment outcomes. Every year, Philips mobile C-arm systems help to treat more than 15 million patients [1] worldwide, underscoring Philips' commitment to delivering accessible and innovative solutions that help physicians to provide better care to more people.

As hospitals and surgical centers face mounting staff shortages and budget constraints, the Philips Zenition mobile C-arm platform is designed to deliver high-quality imaging with ease of use and workflow efficiency. The platform leverages industry leading innovations pioneered on Philips' highly successful Azurion platform, supporting confident clinical decision-making while safeguarding patients and staff. Zenition's compact design, Position Memory feature [2] and BodySmart software, which captures fast and consistent images, reduce the need for C-arm repositioning by 45% [3].

"Designed as an intuitive, impressively fast motorized C-arm, the Zenition efficiently delivers state-of-the-art image quality, said Filip Neumann, MUDr, Head of the Endoscopy Department at Kolín Regional Hospital, where the 5,000th Zenition has been installed. "The tableside operator and touch screen module provide motion and image control directly at the table, giving operators greater flexibility and independence."

A legacy of innovation in mobile surgery imaging
The 5,000th installation coincides with the 70th anniversary of Philips introducing its first mobile C-arm in 1955, marking seven decades of continuous innovation in surgical imaging. Building on this heritage, the Zenition family brings together Philips' expertise in image-guided therapy, workflow innovation, and clinical partnership to improve outcomes across a wide range of surgical specialties.

"Reaching 5,000 Zenition installations worldwide is a testament to the trust clinicians place in our solutions to deliver high-quality care," said Mark Stoffels, Global Business Leader Image-Guided Therapy Systems at Philips.

"This milestone reflects both our rich 70-year heritage in surgical imaging and our continued commitment to helping healthcare providers overcome today's challenges of staff shortages, efficiency pressures, and rising costs - so that more patients everywhere can benefit from safe, effective surgical care," added Rohit Sathe, Global Business Leader, Mobile Surgery at Philips.

From Europe, North America, Middle East & Turkey to Asia and emerging markets, hospitals worldwide are endorsing Zenition for its ease of use, reliability, and clinical versatility. With flexible configurations and upgradability, the platform helps healthcare providers stay ahead of evolving clinical needs while ensuring long-term value.

For more information about Philips range of Zenition mobile X-ray systems, visit our website.

[1] Philips lives improved methodology
[2] Available on Zenition 90 Motorized, Zenition 90, Zenition 70 and Zenition 30 only.
[3] Results obtained during user tests performed in November 2013 by Use-Lab GmbH, an independent company. The tests involved 30 USA-based clinicians (15 physicians teamed up with 15 nurses or X-ray technicians), who performed simulated procedures using Philips mobile X-ray systems in a simulated OR environment. None of them had worked with each other before.

For further information, please contact:

Joost Maltha
Philips Global External Relations
Tel.: +31 6 1055816
E-mail: joost.maltha@philips.com

About Royal Philips

Royal Philips.

Attachment

  • Vascular case with Zenition (https://ml-eu.globenewswire.com/Resource/Download/cf8de94a-3264-45b6-bccf-5762ac16b879)

© 2025 GlobeNewswire (Europe)
Epische Goldpreisrallye
Der Goldpreis hat ein neues Rekordhoch überschritten. Die Marke von 3.500 US-Dollar ist gefallen, und selbst 4.000 US-Dollar erscheinen nur noch als Zwischenziel.

Die Rallye wird von mehreren Faktoren gleichzeitig getrieben:
  • · massive Käufe durch Noten- und Zentralbanken
  • · Kapitalflucht in sichere Häfen
  • · hohe Nachfrage nach physisch besicherten Gold-ETFs
  • · geopolitische Unsicherheit und Inflationssorgen

Die Aktienkurse vieler Goldproduzenten und Explorer sind in den vergangenen Wochen regelrecht explodiert.

Doch es gibt noch Titel, die Nachholpotenzial besitzen. In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Goldaktien jetzt besonders aussichtsreich sind und warum der Aufwärtstrend noch lange nicht vorbei sein dürfte.

Laden Sie jetzt den Spezialreport kostenlos herunter und profitieren Sie von der historischen Gold-Hausse.

Dieses Angebot gilt nur für kurze Zeit – also nicht zögern, jetzt sichern!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.